Meeting
2018 ASCO Annual Meeting
Management and outcomes of 222 CLL patients (pts) treated with venetoclax (VEN) in the real world.
Authors
Chadi Nabhan
Cardinal Health Specialty Solutions, Dublin, OH
Chadi Nabhan , Andrew Klink , Jennifer Samp , James Michael Pauff , Jackie Nielsen , Brian Meissner , Holger Keim , Kaitlin Kennard , Anthony R. Mato
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Sub Track
Chronic Lymphocytic Leukemia (CLL) and Hairy Cell
Citation
J Clin Oncol 36, 2018 (suppl; abstr 7529)
DOI
10.1200/JCO.2018.36.15_suppl.7529
Abstract #
7529
Poster Bd #
166
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Updated efficacy and safety results of BCL-2 inhibitor lisaftoclax (APG-2575) alone or combined with ibrutinib or rituximab in patients (pts) with Waldenström macroglobulinemia (WM).
First Author: Masa Lasica
Poster
2023 ASCO Annual Meeting
Fixed-duration ibrutinib + venetoclax for first-line treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): 4-y follow-up from the FD cohort of the phase 2 CAPTIVATE study.
First Author: Paul M. Barr
Poster
2022 ASCO Annual Meeting
Efficacy and safety of venetoclax in combination with azacitidine or decitabine in an outpatient setting in patients with untreated acute myeloid leukemia.
First Author: Sudhir Manda
Poster
2022 ASCO Annual Meeting
A phase Ib/II study of lisaftoclax (APG-2575), a novel BCL-2 inhibitor (BCL-2i), in patients (pts) with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (R/R CLL/SLL).
First Author: Jianyong Li